Lantern Pharma (NASDAQ:LTRN – Get Free Report) was downgraded by equities researchers at Rodman & Renshaw from a “buy” rating to a “neutral” rating in a report released on Wednesday, Marketbeat.com reports.
Several other equities analysts also recently weighed in on the company. Weiss Ratings downgraded Lantern Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, November 11th. Wall Street Zen cut shares of Lantern Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Reduce”.
Read Our Latest Stock Analysis on Lantern Pharma
Lantern Pharma Trading Down 13.8%
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Susquehanna International Group LLP purchased a new stake in shares of Lantern Pharma in the 2nd quarter valued at approximately $59,000. Empery Asset Management LP acquired a new stake in shares of Lantern Pharma in the 2nd quarter valued at $3,513,930. BlackRock Inc. purchased a new stake in shares of Lantern Pharma during the 2nd quarter worth $93,000. Bank of New York Mellon Corp purchased a new stake in shares of Lantern Pharma during the 2nd quarter worth $89,000. Finally, Renaissance Technologies LLC lifted its position in shares of Lantern Pharma by 5.1% during the 1st quarter. Renaissance Technologies LLC now owns 116,000 shares of the company’s stock worth $159,000 after purchasing an additional 5,600 shares during the last quarter. Institutional investors and hedge funds own 28.62% of the company’s stock.
Lantern Pharma Company Profile
Lantern Pharma is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. It uses its artificial intelligence and machine-learning platform, RADR, to analyze cancer data and help identify drug candidates, potential biomarkers and patient groups that may respond to treatment. The company’s development pipeline includes investigational therapies for several cancers. Its candidates include LP-300, being studied for certain patients with non-small cell lung cancer, and LP-184 and LP-284, which are being developed for selected solid tumors and blood cancers.
See Also
- Five stocks we like better than Lantern Pharma
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Lantern Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantern Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
